Clinical trials: Cancer Esophagus
Barrett Esophagus, Esophageal Cancer
Microbiome Involvement With Barrett's Esophagus and Progression to Esophageal Adenocarcinoma
This study will examine the hypothesis that altered esophageal microbiome leads to the development of esophageal adenocarcinoma (EAC).
- Trial name
- NCT03216135
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ochsner Health System
Gastrooesophageal Cancer
Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
Multicentre, single arm, open label UK phase II trial to assess the efficacy of trastuzumab deruxtecan in reducing micrometastatic disease burden in HER2 positive GOA patients who are ctDNA positive after chemotherapy and…
- Trial name
- DECIPHER (NCT05965479)
- Testing
- Trastuzumab deruxtecan
- Where
- 14 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- University of Southampton
Barrett Metaplasia
Tamoxifen to Treat Barrett's Metaplasia
Treat Barrett's esophagus (BE) patients with tamoxifen to Barrett's metaplasia as measured by changes in Barrett's esophagus appearance by endoscopy and histology as well as changes in SOX2 and CDX2.
- Trial name
- NCT02089386
- Testing
- Tamoxifen, Endoscopy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Washington University School of Medicine
Anal Cancer, Colorectal Cancer
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00003427
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Barrett's Esophagus
Early Increase in Blood Supply in Patients With Barrett's Esophagus
The purpose of this study is to determine if early Barrett's specialized intestinal metaplasia can be detected by measuring early increased blood supply of the esophageal tissue, with 4 Dimensional Elastic Light-Scattering…
- Trial name
- EIBS in BE (NCT01188980)
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Barretts Esophagus With High Grade Dysplasia, Barrett Adenocarcinoma
Endoscopic Mucosal Resection and Cellular Matrix
This study is being done to test the usefulness of extracellular matrix (ECM) a thin sheet placed over the site after endoscopic mucosal resection to promote healing of the esophagus.
- Trial name
- NCT03240679
- Testing
- Acell MatriStem® Surgical Matrix
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Perforation Esophagus, Esophageal Cancer
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
Open, prospective, one-arm feasibility and efficacy study of a European conformity (CE) certified Combination product of two CE certified medical devices in the intended indication.
- Conditions
- Perforation Esophagus, Esophageal Cancer, Esophageal Achalasia, Esophageal Diseases
- Trial name
- VACStent (NCT03962179)
- Testing
- VACStent
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital of Cologne
Esophageal Cancer
ALDH2 Single Nucleotide Polymorphisms and Prognosis of Esophageal Cancer Patients
Alcohol consumption, smoking, and betel nut chewing have been proven to be closely associated with the risk of esophageal cancer (EC).
- Trial name
- NCT07322627
- Where
- Taiwan
- Volunteers
- 700 people
- Sponsor
- National Taiwan University Hospital
Adenocarcinoma
Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer
The primary aim of this dose-finding study is to determine the maximum tolerated dose of taxotere, eloxatin and capecitabine (TEX) in combination with herceptin given every third week as first-line treatment in patients with…
- Trial name
- NCT01295086
- Testing
- Docetaxel, Oxaliplatin, Capecitabine
- Where
- 4 sites in Denmark
- Volunteers
- 27 people
- Sponsor
- Odense University Hospital
Oesophageal Cancer
Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation
Research has shown that increasing the dose of radiotherapy improves outcomes in patients with lung and head and neck cancers. This study aims to see whether this is also the case for patients with tumour of the oesophagus.
- Trial name
- SCOPE2 (NCT02741856)
- Testing
- Carboplatin, Paclitaxel, Cisplatin
- Where
- 26 sites in United Kingdom
- Volunteers
- 584 people
- Sponsor
- Lisette Nixon
Esophageal Cancer
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma (ESCC). Aim to evaluate the efficacy and safety of Iparomlimab consolidation therapy following concurrent…
- Trial name
- NCT07038629
- Testing
- S1, Iparomlimab, Radiation
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastroparesis, Esophageal Cancer
G-POEM for Refractory Gastroparesis After Esophagectomy With Gastric Pull-through
This is a retrospective study assessing the effectiveness of endoscopic pyloromyotomy in patients suffering from gastroparesis and/or symptoms of delayed gastric emptying after esophagectomy with gastric pull-through.
- Trial name
- GESOM (NCT06068127)
- Where
- 2 sites in Czechia, France
- Volunteers
- 30 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00003103
- Testing
- oblimersen sodium, docetaxel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophagus Cancer
The Effect of Parenteral Nutrition Supplement on Esophagectomy Patients
Malnutrition is common in esophagus cancer patients, especially after surgery therapy. Whether parenteral supplement with enteral nutrtion is benificial for patients after esophagectomy is controversial, when compared with…
- Trial name
- NCT01669356
- Testing
- Parenteral supplement with enteral nutrition for patients after esophagectomy, Enteral Nutrition alone for patients after esophagectomy
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Carcinoma, Minimal Residual Disease
Minimally Residual of Esophageal Cancer 001
This trial aims to assess changes in minimal residual disease (MRD) status before and after radical concurrent chemoradiotherapy combined with immunotherapy and adjuvant immunotherapy after neoadjuvant immunochemotherapy in…
- Trial name
- ECMRD-001 (NCT05952661)
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Hebei Medical University Fourth Hospital
Esophageal Cancer
Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors
RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and…
- Trial name
- NCT00060268
- Testing
- HPPH
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Esophagus Cancer
Apatinib Treatment for Advanced Esophagus Cancer
Subject ever received a standard chemotherapy solution progression or recurrence or can't tolerate chemotherapy with advanced esophageal squamous carcinoma.
- Trial name
- NCT03170310
- Testing
- Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Endometrial Cancer, Esophageal Cancer
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen.
- Conditions
- Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer
- Trial name
- NCT04044859
- Testing
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 120 people
- Sponsor
- USWM CT, LLC
Esophageal Cancer
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with recurrent or metastatic…
- Trial name
- NCT00268346
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
Esophageal Neoplasms, Adverse Drug Event
Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer
This study is a randomized, open, parallel controlled clinical trial. The main purpose of this study was to compare the changes in body weight/body mass index (BMI) before and after treatment between the two groups of patients…
- Trial name
- NCT05800054
- Testing
- Nutritional Support Team, Docetaxel, cisplatin
- Where
- China
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.